DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Phase 1

Recruiting

Conditions: Advanced MTAP-null Solid Tumors

Interventions: Drug: AMG 193
Drug: Docetaxel
Drug: Comparator AMG 193 Test Tablet

First Posted Date: 2021-10-26

Last Posted Date: 2025-05-14

Lead Sponsor: Amgen

Target Recruit Count: 649

Registration Number: NCT05094336

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
California Research Institute, Glendale, California, United States
🇺🇸
Fomat Medical Research, Oxnard, California, United States

and more 71 locations

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Adalimumab
Drug: ABP 501

First Posted Date: 2021-10-11

Last Posted Date: 2024-02-09

Lead Sponsor: Amgen

Target Recruit Count: 425

Registration Number: NCT05073315

Locations: 🇺🇸
Johnson Dermatology Clinic, Fort Smith, Arkansas, United States
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
Clinical Science Institute, Santa Monica, California, United States

and more 85 locations

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Small Cell Lung Cancer

Interventions: Drug: Tarlatamab

First Posted Date: 2021-09-28

Last Posted Date: 2025-05-02

Lead Sponsor: Amgen

Target Recruit Count: 222

Registration Number: NCT05060016

Locations: 🇺🇸
University of Pittsburgh Medical Center Cancer Pavillion, Pittsburgh, Pennsylvania, United States
🇬🇷
Metropolitan Hospital, Athens, Greece
🇬🇷
Agios Loukas Clinic, Thessaloniki, Greece

and more 77 locations

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: AMG 133

First Posted Date: 2021-09-24

Last Posted Date: 2025-02-25

Lead Sponsor: Amgen

Target Recruit Count: 34

Registration Number: NCT05056246

Locations: 🇺🇸
WCCT Global LLC, Cypress, California, United States

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Phase 3

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Bemarituzumab
Drug: mFOLFOX6
Drug: Placebo

First Posted Date: 2021-09-22

Last Posted Date: 2025-02-07

Lead Sponsor: Amgen

Target Recruit Count: 547

Registration Number: NCT05052801

Locations: 🇬🇷
251 General Airforce Hospital, Athens, Greece
🇬🇷
General Hospital of Athens Laiko, Athens, Greece
🇬🇷
Evgenidio Hospital I Agia Trias, Athens, Greece

and more 296 locations

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rosuvastatin
Drug: Sotorasib

First Posted Date: 2021-09-16

Last Posted Date: 2023-08-14

Lead Sponsor: Amgen

Target Recruit Count: 13

Registration Number: NCT05045638

Locations: 🇺🇸
Covance Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: HZN-825
Drug: Placebo

First Posted Date: 2021-09-02

Last Posted Date: 2025-03-06

Lead Sponsor: Amgen

Target Recruit Count: 153

Registration Number: NCT05032066

Locations: 🇿🇦
Dr. Ismail Abdullah Private Practice, Cape Town, Western Cape, South Africa
🇦🇷
Instituto De Enfermedades Respiratorias E Investigacion Medica, Florencio Varela, Buenos Aires, Argentina
🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 79 locations

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Phase 4

Active, not recruiting

Conditions: Thyroid Eye Disease

Interventions: Drug: Teprotumumab
Drug: Placebo

First Posted Date: 2021-08-12

Last Posted Date: 2024-10-18

Lead Sponsor: Amgen

Target Recruit Count: 313

Registration Number: NCT05002998

Locations: 🇺🇸
The Private Practice of Raymond Douglas, MD - Beverly Hills, Beverly Hills, California, United States
🇺🇸
University of Colorado - Eye Center - PPDS, Aurora, Colorado, United States
🇺🇸
Mayo Clinic - PPDS, Rochester, Minnesota, United States

and more 26 locations

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1

Withdrawn

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: AMG 701

First Posted Date: 2021-08-10

Last Posted Date: 2022-09-27

Lead Sponsor: Amgen

Registration Number: NCT04998747

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

Phase 3

Recruiting

Conditions: Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: SOC chemotherapy regimen
Drug: Blinatumomab
Drug: Low-intensity chemotherapy regimen

First Posted Date: 2021-08-06

Last Posted Date: 2025-05-14

Lead Sponsor: Amgen

Target Recruit Count: 284

Registration Number: NCT04994717

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 165 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy